BSX

Business Context and Reporting Period

Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Overview: A worldwide developer, manufacturer, and marketer of less-invasive medical devices. The quarter was defined by the consummation of the acquisition of Guidant Corporation on April 21, 2006, shortly after the reporting period, which significantly altered the company's capital structure and product portfolio.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Net sales remained flat on a reported basis (+0.3%) but grew 3% on a constant currency basis. U.S. sales declined 1% due to reduced market share and pricing pressure on the TAXUS stent system, while international sales grew 3% (10% constant currency).
• Profitability: Gross margin decreased 1.8 percentage points due to sales mix shifts and pricing erosion. Operating income declined 3% primarily due to increased operating expenses.
• Expenses: Selling, General, and Administrative (SG&A) expenses rose 9% ($39 million) due to headcount expansion and the adoption of FASB Statement No. 123(R) for stock-based compensation. R&D expenses increased 17% ($27 million) driven by new acquisitions and internal projects.
• One-Time Charges: Q1 2006 included $49 million in after-tax charges (stock-based compensation and gene therapy trial write-downs). Q1 2005 included a $73 million after-tax charge for purchased R&D.
• Debt: Borrowings increased significantly to $2.642 billion (from $2.020 billion at year-end 2005) to fund the Guidant acquisition and reimburse a merger termination fee to Guidant.

Guidance, Outlook, and Risks

• Guidant Acquisition: The $27.5 billion acquisition of Guidant (closed April 21, 2006) is expected to significantly dilute 2006 earnings per share. The company plans to issue up to $1.5 billion in senior notes in Q2 2006 to refinance interim debt.
• Product Outlook: Management expects to launch the TAXUS Liberté stent in the U.S. late in 2006. International conversion to drug-eluting stents is accelerating (52% in Europe/Inter-Continental vs. 40% prior year).
• Regulatory Risks: The FDA issued a corporate warning letter in January 2006 citing serious regulatory problems at three facilities. Failure to remediate could lead to product seizures or injunctions. Guidant also faces FDA warning letters regarding quality systems.
• Legal Contingencies: Significant intellectual property litigation exists with Johnson & Johnson, Medtronic, and others. The acquisition of Guidant added substantial product liability and securities litigation exposure, including over 66 class action lawsuits related to Guidant's defibrillators.
• Reimbursement: Proposed CMS rule changes for 2007 could reduce reimbursement rates for ICDs and drug-eluting stents by approximately 20% or more.

Investor Verification Checklist

• Integration Costs: Verify the magnitude of integration and restructuring costs associated with the Guidant merger and the timeline for realizing synergies.
• Regulatory Remediation: Confirm the status of corrective actions taken in response to the FDA warning letters issued to both Boston Scientific and Guidant.
• Debt Servicing: Assess the impact of increased interest rates (weighted average 5.69%) and the ability to refinance the $6.6 billion in new debt incurred for the acquisition.
• Stent Market Share: Monitor the stabilization of U.S. market share for the TAXUS stent system against new competitors entering the market.
• Legal Exposure: Review the potential financial impact of the inherited Guidant litigation, particularly regarding the ANCURE endograft system and defibrillator product recalls.